Madrigal Pharmaceuticals, Inc. last reported quarterly results on Nov 3, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $431.3 million (+50.1% year over year) and diluted EPS of $1.83. It usually reports 30–50 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 18, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Feb 19, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 30–50 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 3, 2026
34 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
431
+50.1%
|
55
+148.6%
|
1.83
+145.6%
|
|
Jul 30, 2026
30 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
364
+71.2%
|
-58
-37.0%
|
-1.99
-32.7%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
311
+126.8%
|
-94
-28.9%
|
-3.25
-24.5%
|
|
Feb 19, 2026
50 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
321
+210.8%
|
-59
+1.4%
|
-2.03
-51.6%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
287
+362.0%
|
-114
-6.8%
|
-4.01
+18.5%
|
|
Aug 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
213
+1353.8%
|
-42
+72.2%
|
-1.50
+78.9%
|
|
May 1, 2025
31 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
137
|
-73
+50.4%
|
-2.61
+64.6%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
103
|
-59
+47.0%
|
-1.34
+76.4%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MDGL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- West Conshohocken, PA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1157601
- Former names
- MADRIGAL PHARMACEUTICALS, INC. (until Nov 3, 2026); SYNTA PHARMACEUTICALS CORP (until Aug 1, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.